Prognostic and clinicopathological value of osteopontin expression in non-small cell lung cancer: a meta-analysis and systematic review

References

• Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch KS, Jonker A, De Witt Hamer PC, Troost D, McCulloch CA, et al. 2011. Osteopontin is up-regulated and associated with neutrophil and macrophage ­infiltration in glioblastoma. Immunology. 132(1):39–48. doi: 10.1111/j.1365-2567.2010.03335.x
   PubMed Web of Science ®Google Scholar
• Boldrini L, Donati V, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, et al. 2005. Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer. 93(4):453–457. doi: 10.1038/sj.bjc.6602715
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424. doi: 10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Carbone F, Grossi F, Bonaventura A, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, Rijavec E, et al. 2019. Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. Clin Exp Metastasis. 36(5):449–456. doi: 10.1007/s10585-019-09984-z
   PubMed Web of Science ®Google Scholar
• Chakraborty G, Jain S, Kundu GC. 2008. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 68(1):152–161. doi: 10.1158/0008-5472.CAN-07-2126
   PubMed Web of Science ®Google Scholar
• Crawford HC, Matrisian LM, Liaw L. 1998. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res. 58(22):5206–5215.
   PubMed Web of Science ®Google Scholar
• Cui R, Takahashi F, Ohashi R, Gu T, Yoshioka M, Nishio K, Ohe Y, Tominaga S, Takagi Y, Sasaki S, et al. 2007. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer. 57(3):302–310. doi: 10.1016/j.lungcan.2007.03.019
   PubMed Web of Science ®Google Scholar
• Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, van der Weide H, Rao B, Lambin P. 2011. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys. 81(2):360–368. doi: 10.1016/j.ijrobp.2010.06.011
   PubMed Web of Science ®Google Scholar
• Denhardt DT, Giachelli CM, Rittling SR. 2001. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol. 41(1):723–749. doi: 10.1146/annurev.pharmtox.41.1.723
   PubMedGoogle Scholar
• Donati V, Boldrini L, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, et al. 2005. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res. 11(18):6459–6465. doi: 10.1158/1078-0432.CCR-05-0541
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D’Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, et al. 2017. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 15(4):504–535. doi: 10.6004/jnccn.2017.0050
   PubMed Web of Science ®Google Scholar
• Fan X, He C, Jing W, Zhou X, Chen R, Cao L, Zhu M, Jia R, Wang H, Guo Y, et al. 2015. Intracellular Osteopontin inhibits toll-like receptor signaling and impedes liver carcinogenesis. Cancer Res. 75(1):86–97. doi: 10.1158/0008-5472.CAN-14-0615
   PubMed Web of Science ®Google Scholar
• Fidler MJ, Fhied CL, Roder J, Basu S, Sayidine S, Fughhi I, Pool M, Batus M, Bonomi P, Borgia JA. 2018. The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 18(1):310. doi: 10.1186/s12885-018-4193-0
   PubMedGoogle Scholar
• Han SS, Lee SJ, Kim WJ, Ryu DR, Won JY, Park S, Cheon MJ. 2013. Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer. Tuberc Respir Dis (Seoul)). 75(3):104–110. doi: 10.4046/trd.2013.75.3.104
   PubMedGoogle Scholar
• Hao C, Cui Y, Lane J, Jia S, Ji J, Jiang WG. 2021. Distinctive prognostic value and cellular functions of osteopontin splice variants in human gastric cancer. Cells. 10(7):1820. doi: 10.3390/cells10071820
   PubMed Web of Science ®Google Scholar
• Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, et al. 2005. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res. 11(13) :4646–4652. doi: 10.1158/1078-0432.CCR-04-2013
   PubMed Web of Science ®Google Scholar
• Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, Yonei T, Hayashibara K, Fukushima M, Kawahara M, et al. 2009. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol. 4(9):1104–1110. doi: 10.1097/JTO.0b013e3181ae2844
   PubMed Web of Science ®Google Scholar
• Ishiwata T, Takahashi K, Shimanuki Y, Ohashi R, Cui R, Takahashi F, Shimizu K, Miura K, Fukuchi Y. 2005. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res. 25(1b):489–495.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Yao M, Liu Q, Zhou C. 2013. OPN gene polymorphisms influence the risk of knee OA and OPN levels in synovial fluid in a Chinese population. Arthritis Res Ther. 15(1):R3. doi: 10.1186/ar4129
   PubMed Web of Science ®Google Scholar
• Lin Q, Guo L, Lin G, Chen Z, Chen T, Lin J, Zhang B, Gu X. 2015. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer. Cancer Epidemiol. 39(4):539–544. doi: 10.1016/j.canep.2015.05.010
   PubMed Web of Science ®Google Scholar
• Liu F, Bai C, Guo Z. 2017. The prognostic value of osteopontin in limited-stage small cell lung cancer patients and its mechanism. Oncotarget. 8(41):70084–70096. doi: 10.18632/oncotarget.19589
   PubMedGoogle Scholar
• Ma R, Xu H, Wu J, Sharma A, Bai S, Dun B, Jing C, Cao H, Wang Z, She J-X, et al. 2017. Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer. Oncotarget. 8(12):18901–18913. doi: 10.18632/oncotarget.14782
   PubMedGoogle Scholar
• Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le QT, Crowley JJ, Gandara DR. 2008. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 26(29):4771–4776. doi: 10.1200/JCO.2008.17.0662
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 339(1):b2535–b2535. doi: 10.1136/bmj.b2535
   PubMed Web of Science ®Google Scholar
• Ostheimer C, Bache M, Güttler A, Kotzsch M, Vordermark D. 2014. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer: Osteopontin, carbonicanhydrase IX and vascular endothelial growth factor. Strahlenther Onkol. 190(3):276–282. doi: 10.1007/s00066-013-0484-1
   PubMedGoogle Scholar
• Ostheimer C, Bache M, Güttler A, Reese T, Vordermark D. 2014. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer. BMC Cancer. 14(1):858. doi: 10.1186/1471-2407-14-858
   PubMedGoogle Scholar
• Ostheimer C, Gunther S, Bache M, Vordermark D, Multhoff G. 2017. Dynamics of heat shock protein 70 serum levels as a predictor of clinical response in non-small-cell lung cancer and correlation with the hypoxia-related marker osteopontin. Front Immunol. 8:1305. doi: 10.3389/fimmu.2017.01305
   PubMed Web of Science ®Google Scholar
• Ostheimer C, Schweyer F, Reese T, Bache M, Vordermark D. 2016. The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer. Oncol Lett. 12(5):3449–3456. doi: 10.3892/ol.2016.5104
   PubMed Web of Science ®Google Scholar
• Ouyang X, Huang Y, Jin X, Zhao W, Hu T, Wu F, Huang J. 2018. Osteopontin promotes cancer cell drug resistance, invasion, and lactate production and is associated with poor outcome of patients with advanced non-small-cell lung cancer. Onco Targets Ther. 11:5933–5941. doi: 10.2147/OTT.S164007
   PubMed Web of Science ®Google Scholar
• Rangaswami H, Bulbule A, Kundu GC. 2006. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 16(2):79–87. doi: 10.1016/j.tcb.2005.12.005
   PubMed Web of Science ®Google Scholar
• Rouanne M, Adam J, Goubar A, Robin A, Ohana C, Louvet E, Cormier J, Mercier O, Dorfmüller P, Fattal S, et al. 2016. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer. BMC Cancer. 16(1):483. doi: 10.1186/s12885-016-2541-5
   PubMedGoogle Scholar
• Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, Berge G, Helland A, Brustugun OT, Mælandsmo GM. 2013. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer. 13(1):540. doi: 10.1186/1471-2407-13-540
   PubMedGoogle Scholar
• Shi S-M, Su Z-B, Zhao J-J, Yu D-J, Tu J-W, Zhu JQ, Zhao J-P, Sheng L, Wang S-B, Sheng Y-J, et al. 2016. Increased osteopontin protein expression may be correlated with poor prognosis in non-small-cell lung cancer: a meta analysis. J Cancer Res Ther. 12(1):277–282. doi: 10.4103/0973-1482.150362
   PubMed Web of Science ®Google Scholar
• Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, Simmons BH, Wu A, Lee JH, Bergqvist S, et al. 2012. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res. 31(1):26. doi: 10.1186/1756-9966-31-26
   PubMedGoogle Scholar
• Singh R, Hui T, Matsui A, Allahem Z, Johnston CD, Ruiz-Torruella M, Rittling SR. 2017. Modulation of infection-mediated migration of neutrophils and CXCR2 trafficking by osteopontin. Immunology. 150(1):74–86. doi: 10.1111/imm.12668
   PubMed Web of Science ®Google Scholar
• Stang A. 2010. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25(9):603–605. doi: 10.1007/s10654-010-9491-z
   PubMed Web of Science ®Google Scholar
• Sun BS, Li Y, Zhang ZF, You J, Wang CL. 2013. Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg. 96(6):1943–1951. doi: 10.1016/j.athoracsur.2013.07.089
   PubMed Web of Science ®Google Scholar
• Sun T, Li P, Sun D, Bu Q, Li G. 2018. Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Medicine. 97(43):e12954. doi: 10.1097/MD.0000000000012954
   PubMed Web of Science ®Google Scholar
• Sun Y, Li D, Lv XH, Hua SC, Han JC, Xu F, Li XD. 2015. Roles of osteopontin and matrix metalloproteinase-7 in occurrence, progression, and prognosis of non small cell lung cancer. J Res Med Sci. 20(12):1138–1146. doi: 10.4103/1735-1995.172980
   PubMed Web of Science ®Google Scholar
• Suwinski R, Giglok M, Galwas-Kliber K, Idasiak A, Jochymek B, Deja R, Maslyk B, Mrochem-Kwarciak J, Butkiewicz D. 2019. Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer. BMC Cancer. 19(1):427. doi: 10.1186/s12885-019-5617-1
   PubMedGoogle Scholar
• Takenaka M, Hanagiri T, Shinohara S, Yasuda M, Chikaishi Y, Oka S, Shimokawa H, Nagata Y, Nakagawa M, Uramoto H, et al. 2013. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. Clin Lung Cancer. 14(3):288–294. doi: 10.1016/j.cllc.2012.09.005
   PubMed Web of Science ®Google Scholar
• Thakur MK, Gadgeel SM. 2016. Predictive and prognostic biomarkers in non-small cell lung cancer. Semin Respir Crit Care Med. 37(5):760–770. doi: 10.1055/s-0036-1592337
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. 2007. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8(1):16. doi: 10.1186/1745-6215-8-16
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 2015. Global cancer statistics, 2012. CA Cancer J Clin. 65(2):87–108. doi: 10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Wai PY, Guo L, Gao C, Mi Z, Guo H, Kuo PC. 2006. Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery. 140(2):132–140. doi: 10.1016/j.surg.2006.02.005
   PubMed Web of Science ®Google Scholar
• Wang Y, Lu Y, Xu W, Wang Y, Wu Y, Che G. 2019. Prognostic value of osteopontin expression in esophageal squamous cell carcinoma: A meta-analysis. Pathol Res Pract. 215(10):152571. doi: 10.1016/j.prp.2019.152571
   PubMed Web of Science ®Google Scholar
• Weber GF, Lett GS, Haubein NC. 2010. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 103(6):861–869. doi: 10.1038/sj.bjc.6605834
   PubMed Web of Science ®Google Scholar
• Yu A, Guo K, Qin Q, Xing C, Zu X. 2021. Clinicopathological and prognostic significance of osteopontin expression in patients with prostate cancer: a systematic review and meta-analysis. Biosci Rep. 41(8):BSR20203531. doi: 10.1042/BSR20203531
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ, Ling XL, Ma SC. 2014. The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis. J Mol Histol. 45(5):533–540. doi: 10.1007/s10735-014-9574-3
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang DM, Zhao D, Hou XM, Yang TN. 2014. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer. J Buon. 19(3):742–748.
   PubMed Web of Science ®Google Scholar
• Zlobec I, Günthert U, Tornillo L, Iezzi G, Baumhoer D, Terracciano L, Lugli A. 2009. Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology. 55(5):564–575. doi: 10.1111/j.1365-2559.2009.03421.x
   PubMed Web of Science ®Google Scholar